January 20, 2022
argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis
Breda, the Netherlands – Jan. 20, 2022
argenx SE today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). VYVGART is the first-and-only neonatal Fc receptor (FcRn) blocker approved in Japan.
Past Press Releases
Get photos, fact sheets, illustrations and more.
Join the team
Dare to do more with a thriving career at Argenx.
Get the latest news and info via our social media channels.